HAE:NYSEHaemonetics Corporation Analysis

Haemonetics is trading well below its DCF-derived fair value, offering roughly a 50% upside potential while maintaining solid profitability margins and a healthy operating cash flow. Technical signals are mixed: the stock sits above its 20‑day moving average but below the 50‑day and 200‑day averages, RSI hovers near the neutral 50 mark, and a bullish MACD histogram suggests short‑term momentum could turn positive. Fundamentally, revenue is slightly contracting, yet gross and operating margins remain robust, and forward earnings estimates imply a meaningful earnings expansion. The balance sheet is leveraged, with a debt‑to‑equity ratio exceeding 130%, but ample cash and strong free cash flow provide a cushion. Recent news highlights a thriving plasma collection business and new product approvals (VASCADE MVP XL), which should sustain top‑line growth despite competitive pressures in interventional technologies.